AbCellera Biologics Inc (NASDAQ:ABCL) currently has a daily average trading volume of 5.45M but it saw 6972127 shares traded in last market. With a market cap of 1.26B USD, the company’s current market price of $4.22 came rising about 8.48 while comparing to the previous closing price of $3.89. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.11 and as low as $1.89. In the recent trading on the day, stock has struck highest price mark of $3.9 while lowest mark touched by it was $4.285.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Leerink Partners which resumed the stock as “Outperform” in its note to investors issued on July 07, 2025, recommending a price target of $5 for it. The Benchmark Company issued its recommendations for the stock as it upgraded the price target for the stock is $9.
Over the week, ABCL’s stock price is moving 20.92% up while it is 72.95% when we observe its performance for the past one month. Year-to-date it is 56.88% up and over the past year, the stock is showing an upside performance of 44.03%.
The company is expected to be releasing its next quarterly report on 2025-May-08, for which analysts forecasted an EPS of -0.16 while estimate for next year EPS is -0.64. In next quarter, company is expected to be making quarterly sales of $7.57M as analysts are expecting the sales for current fiscal year at $26.06M and seeing the company making $52.58M in sales next year. Moreover, analysts are in estimates of $7.55M for current-quarter revenue.
Currently, AbCellera Biologics Inc’s total number of outstanding shares is 298.36M. Company’s return on investment (ROI) stands at -15.45% and return on equity (ROE) at -15.59%. Stock’s beta reads 0.61. Stock has a price to book (P/B) ratio of 1.23 while price to sale or P/S ratio amounts to 54.48. Its return on asset (ROA) is -11.96% on average.
